ASSESSMENT OF NT-PROBNP LEVELS IN PATIENTS WITH CARDIAC ARRHYTHMIAS

Abstract

Background: NT-proBNP is a valuable biomarker for the diagnosis and treatment of cardiovascular diseases, including arrhythmias. Objective: To evaluate NT-proBNP levels in patients with arrhythmias and analyze the correlation between NT-proBNP levels and several variables. Subjects and Methods: A cross-sectional descriptive study was conducted on 158 patients with arrhythmias from December 2023 to March 2024 at the Arrhythmias Treatment Department of Cho Ray Hospital. Clinical and paraclinical characteristics were analyzed; NT-proBNP levels were compared between patients with arrhythmias with and without heart failure (HF); and the correlation between NT-proBNP levels and several factors was analyzed using R software version 4.3.1. Statistical significance was considered at P < 0.05. Results: The NT-proBNP level (Median [IQR]) in patients with arrhythmias (n = 158) was 367 (61.9-1297) pg/ml. NT-proBNP levels were higher in patients with arrhythmias with HF (n = 41) than in those without HF (n = 117), at 1273 (498-4173) vs. 210 (51-875) pg/ml (P < 0.001). Univariate analysis showed that age, weight, HGB, EF, creatinine, and eGFR were statistically significantly correlated with NT-proBNP. Conclusions: The NT-proBNP level in patients with arrhythmias was 367.3 (61.9-1297) pg/ml; it was higher in patients with arrhythmias with HF than in those without HF. NT-proBNP level was statistically significantly correlated with age, weight, HGB, EF, creatinine, and eGFR.